Phase I/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large-cell lymphoma - Ogura, M; Tobinai, K; Hatake, K (Cancer Sci, 2014)
et al.